Multiple Myeloma, Version 1.2013

View More View Less
  • 1 From Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center; Moffitt Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Michigan Comprehensive Cancer Center; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UNMC Eppley Cancer Center at The Nebraska Medical Center; Duke Cancer Institute; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Memorial Sloan-Kettering Cancer Center; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute; and National Comprehensive Cancer Network.
Restricted access

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.

Supplementary Materials

    • Supplemental Material (PDF 377 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 199 141 9
PDF Downloads 58 45 8
EPUB Downloads 0 0 0